galantamine and Cognition Disorders

galantamine has been researched along with Cognition Disorders in 92 studies

Research

Studies (92)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	63 (68.48)	29.6817
2010's	29 (31.52)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hoffman, D; Howlett, SE; Mitnitski, A; Rockwood, K; Schindler, R	1
Bradley, J; Chan, P; Herrmann, N; Lanctôt, K; Mohammad, D	1
Arias, HR; Manetti, D; Romanelli, MN; Wadenberg, MG	1
Fang, T; Guo, A; Huang, XF; Liu, Y; Luo, X; Newell, KA; Yang, X; Yu, Y; Zhang, Y; Zheng, X	1
Gu, W; Hou, Y; Luan, Y; Wang, T; Wu, H; Xiao, C; Zhou, C; Zhu, H	1
Arizaga, RL; Demey, I; Rojas, G	1
Brown, CH; Deutsch, SI; Rosse, RB; Rosse, SM; Schooler, NR; Schwartz, BL	1
Birks, J; Craig, D	2
Al-Onaizi, MA; Barbash, S; Bartha, R; Guzman, MS; Hirata, PH; Kolisnyk, B; Nikolova, S; Prado, MA; Prado, VF; Soreq, H	1
Ahn, IS; Carroll, BJ; Hwang, TY; Kang, HS; Kim, DK; Ku, HM; Lee, Y; Myung, W; Song, J; Woo, SY	1
Aaronson, ST; Aitchison, KJ; Buchanan, RW; Dickerson, FB; Koola, MM; Pillai, A; Weinberger, DR	1
Adeghate, E; Devavaram Jackson, D; Jebasingh, D; Starling Emerald, B; Venkataraman, S	1
Du, W; Li, M; Shao, F; Shao, S; Wang, W	1
Babri, S; Mahmoudi, J; Sadigh-Eteghad, S; Shanehbandi, D; Talebi, M	1
Bogolepova, AN	1
Andaluz, N; Flashman, LA; George, MS; Grant, GA; He, F; Jain, S; Lohr, JB; McAllister, TW; Paulus, MP; Raman, R; Stein, MB; Summerall, L; Zafonte, R	1
Creeden, C; George, TP; Reutenauer, EL; Sacco, KA	1
Chuang, TT; Gil-Bea, FJ; Marcos, B; Ramirez, MJ	1
Butters, M; Cabacungan, L; Dew, MA; Koenig, K; Lenze, EJ; Mulsant, BH; Munin, MC; Penrod, L; Pollock, BG; Reynolds, CF; Skidmore, E; Whyte, EM	1
Amick, MM; Friedman, JH; Grace, J	1
Frolich, L; Gertz, HJ; Hampel, H; Henn, F; Heuser, I; Hüll, M; Jahn, H; Jessen, F; Kornhuber, J; Luckhaus, C; Maier, W; Pantel, J; Perneczky, R; Peters, O; Rienhoff, O; Rüther, E; Schmidtke, K; Schröder, J; Seuchter, SA; Weih, M; Wiltfang, J; Wolf, S	1
Bauer, AD; Chriki, L; Dunn, RT; Filkowski, MM; Ghaemi, SN; Gilmer, WS; Hanlon, RE; Harvey, PD; Kemp, DE	1
Ilavazhagan, G; Maiti, P; Muthuraju, S; Prasad, D; Sharma, AK; Singh, SB; Solanki, P	1
Kano, M; Kurinami, H; Morishita, R; Niisato, K; Rakugi, H; Sato, N; Shinohara, M; Takeda, S; Takeuchi, D	1
Bokde, AL; Born, C; Hampel, H; Karmann, M; Lieb, M; Möller, HJ; Reiser, MF; Teipel, SJ	1
Fay, S; Gorman, M; Rockwood, K	1
Hoeffle-Maas, A; Jordis, U; Koepke, AK; Ludwig, J; Maelicke, A; Maus, A; Samochocki, M	1
Deckersbach, T; Iosifescu, DV; Moore, CM; Nierenberg, AA; Ostacher, MJ; Sachs, GS; Tilley, CA	1
Khan, A; Lindenmayer, JP	1
Ago, Y	1
Kumar, A; Pahwa, D; Prakash, A	1
Albuquerque, EX; Kulkarni, GS; Mamczarz, J; Pereira, EF	1
Kavanagh, S; Schäuble, B; Van Baelen, B	1
Alexander, KS; Bruno, JP; Schwarcz, R; Wu, HQ	1
Gray, SL; McDermott, CL	1
Ago, Y; Matsuda, T; Takuma, K	1
Kanno, T; Nishizaki, T; Shimizu, T; Tanaka, A; Yaguchi, T	1
Al Owesie, RM; Morton, CS	1
Khaĭmov, DA; Khalimov, RR; Krasakov, IV; Litvinenko, IV; Trufanov, AG	1
Erkinjuntti, T	1
Bowler, JV	1
Doody, RS	1
Gutterman, EM; Lilienfeld, S; Markowitz, JS; Papadopoulos, G	1
Ihl, R	1
Aarsland, D; Hutchinson, M; Larsen, JP	1
Erkinjuntti, T; Feldman, H; Gauthier, S; Rockwood, K; Román, G	1
Kaufer, DI	1
Bardelli, F; Bencini, F; Biagini, CA; Caleri, V; Cantini, C; Cavallini, MC; Marini, M; Masotti, G; Mecacci, R; Mossello, E; Razzi, E; Sarcone, E; Tilli, S; Tonon, E	1
Catte, O; Cossu, G; Maccioni, E; Melis, G; Melis, M; Putzu, PF; Putzu, V	1
Barkhof, F; Goekoop, R; Hibbel, A; Jonker, C; Knol, DL; Rombouts, SA; Scheltens, P; Truyen, L	1
Tenovuo, O	1
Mayor, S	1
Harry, RD; Zakzanis, KK	1
Caffari, B; Maggini, M; Martini, N; Raschetti, R; Sorrentino, GC; Vanacore, N	1
Bennouna, M; Defranoux, L; Greene, VB	1
Scheltens, P; Verhey, FR; Visser, PJ	1
Brashear, HR	1
Barkhof, F; Goekoop, R; Rombouts, SA; Scheltens, P	1
Brandenburg, I; Grön, G; Riepe, MW; Wunderlich, AP	1
Jelic, V; Kivipelto, M; Winblad, B	1
Loy, C; Schneider, L	1
Ghaemi, SN; Schrauwen, E	1
Fay, S; Gorman, M; MacKnight, C; Rockwood, K; Song, X	1
Björner, A; Eriksson, L; Norén, U; Sonesson, O	1
Beck, C; Blank, K; Colenda, CC; Doraiswamy, MP; Kalunian, DA; Lyketsos, CG; Yaffe, K	1
Brissos, S; Dias, VV; Gorman, JM	1
Chilovi, BV; Costardi, D; Franzoni, S; Padovani, A; Rozzini, L; Trabucchi, M	1
Chen, W; Mizoguchi, H; Mouri, A; Nabeshima, T; Nitta, A; Noda, Y; Wang, D; Zhou, Y	1
Agbokou, C; Ferreri, F; Gauthier, S	1
Amatniek, J; Jelic, V; Kershaw, P; Winblad, B	1
Kim, YH; Lee, BJ; Lee, JG; Lee, SW	1
Ho, J; McLay, RN	1
Chen, Y; Guo, L; Ji, X; Li, C; Lu, Y	1
Campanozzi, MD; Casali, E; Martini, E; Neri, M; Neviani, F	1
Candelise, L; Cantisani, TA; Celani, MG; Cusi, C; Incorvaia, B; Righetti, E	1
Auchus, AP; Brashear, HR; De Deyn, PP; Gassmann-Mayer, C; Korczyn, AD; Salloway, S	1
Baity, M; Blais, M; Fava, M; Homberger, C; Matthews, JD; Murakami, J; Park, L; Sklarsky, K; Welch, C	1
Agelan, A; Del Valle, L; Woodruff-Pak, DS	1
Fellgiebel, A	1
Barkhof, F; Fox, NC; Korf, ES; Scheltens, P; van de Pol, LA; van der Flier, WM	1
Kircher, T; Leucht, S; Thienel, R; Voss, B	1
Engel, J; Hager, K; Kenklies, M; McAfoose, J; Münch, G	1
Ball, MP; Buchanan, RW; Conley, RR; Dickinson, D; Feldman, S; Gold, JM; McMahon, RP	1
Gorelick, PB; Nyenhuis, DL	1
Ames, D; Ashby, D; Birks, J; Kaduszkiewicz, H; van den Bussche, H; Zimmermann, T	1
Brashear, HR; Feldman, H; Gauthier, S; Mayorga, AJ; Nye, JS; Scinto, L; Truyen, L; Wang, D; Wilcock, GK; Winblad, B	1
Culhane, MA; Deckersbach, T; Dyer, MA; Evins, AE; Freudenreich, O; Goff, DC; Murphy, E; Pachas, GN	1
Aisen, PS	1
Murray, J; Wilkinson, D	1
Mintzer, J; Rockwood, K; Truyen, L; Wessel, T; Wilkinson, D	1

Reviews

16 review(s) available for galantamine and Cognition Disorders

Article	Year
Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. Expert opinion on drug safety, 2017, Volume: 16, Issue:9 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Drug Interactions; Galantamine; Humans; Indans; Piperidines; Rivastigmine; Severity of Illness Index	2017
Galantamine for vascular cognitive impairment. The Cochrane database of systematic reviews, 2006, Jan-25, Issue:4 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Galantamine; Humans; Nootropic Agents; Randomized Controlled Trials as Topic	2006
Drugs for cognitive loss and dementia. Treatment guidelines from the Medical Letter, 2013, Volume: 11, Issue:134 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Rivastigmine	2013
Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophrenia research, 2014, Volume: 157, Issue:1-3 Topics: Animals; Cognition Disorders; Drug Therapy, Combination; Galantamine; Humans; Memantine; Nootropic Agents; Randomized Controlled Trials as Topic; Schizophrenia	2014
[A modern concept of mixed dementia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:5 Topics: Cognition Disorders; Dementia; Galantamine; Humans	2015
[Beneficial effect of galantamine on sensory information-processing deficits]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2010, Volume: 130, Issue:10 Topics: Acetylcholine; Animals; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Galantamine; Humans; Mice; Prefrontal Cortex; Receptors, Muscarinic; Reflex, Startle; Sensation Disorders	2010
Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. The Annals of pharmacotherapy, 2012, Volume: 46, Issue:4 Topics: Antidepressive Agents; Cholinesterase Inhibitors; Cognition Disorders; Depression; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine	2012
[Pharmacological profiles of galantamine: the involvement of muscarinic receptor]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2012, Volume: 32, Issue:1 Topics: Acetylcholine; Animals; Brain; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Galantamine; Humans; Mice; Receptors, Muscarinic	2012
Current treatments for Alzheimer's disease: cholinesterase inhibitors. The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 9 Topics: Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Multicenter Studies as Topic; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2003
A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Human psychopharmacology, 2005, Volume: 20, Issue:3 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Male; Nootropic Agents; Piperidines; Treatment Outcome	2005
Clinical trials in mild cognitive impairment: lessons for the future. Journal of neurology, neurosurgery, and psychiatry, 2006, Volume: 77, Issue:4 Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Lactones; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index; Sulfones; Vitamin E	2006
Galantamine for Alzheimer's disease and mild cognitive impairment. The Cochrane database of systematic reviews, 2006, Jan-25, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Galantamine; Humans; Multicenter Studies as Topic; Nootropic Agents; Randomized Controlled Trials as Topic	2006
Galantamine for vascular cognitive impairment. The Cochrane database of systematic reviews, 2006, Jan-25, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Galantamine; Humans; Nootropic Agents; Randomized Controlled Trials as Topic	2006
Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. Journal of psychiatry & neuroscience : JPN, 2006, Volume: 31, Issue:6 Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Schizophrenic Psychology; Treatment Outcome	2006
[Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview]. Der Nervenarzt, 2008, Volume: 79, Issue:1 Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Physostigmine; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2008
Diagnosis and management of vascular cognitive impairment. Current atherosclerosis reports, 2007, Volume: 9, Issue:4 Topics: Central Nervous System Agents; Clinical Trials as Topic; Cognition Disorders; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine	2007

Trials

32 trial(s) available for galantamine and Cognition Disorders

Article	Year
Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy. Schizophrenia research, 2013, Volume: 148, Issue:1-3 Topics: Adult; Aged; alpha7 Nicotinic Acetylcholine Receptor; Cognition Disorders; Cytidine Diphosphate Choline; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Synaptic Transmission; Treatment Outcome	2013
Cognitive subdomain responses to galantamine in Alzheimer's disease. The Journal of nervous and mental disease, 2014, Volume: 202, Issue:3 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Executive Function; Female; Galantamine; Humans; Male; Memory Disorders; Neuropsychological Tests; Severity of Illness Index; Treatment Outcome	2014
Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2016, Volume: 41, Issue:5 Topics: Adult; Affective Symptoms; Brain Injuries, Traumatic; Cognition Disorders; Double-Blind Method; Female; Galantamine; Humans; Male; Methylphenidate; Middle Aged; Neuropsychological Tests; Pilot Projects; Stress Disorders, Post-Traumatic; Treatment Outcome	2016
Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia. Schizophrenia research, 2008, Volume: 103, Issue:1-3 Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Attention; Cognition Disorders; Double-Blind Method; Female; Galantamine; Humans; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Psychomotor Performance; Schizophrenia; Schizophrenic Psychology; Smoking; Smoking Cessation	2008
An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients. Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 26, Issue:3 Topics: Aged; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Feasibility Studies; Female; Galantamine; Humans; Indans; Male; Middle Aged; Motivation; Motor Activity; Nootropic Agents; Pilot Projects; Piperidines; Prospective Studies; Recovery of Function; Stroke; Treatment Outcome	2008
A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:1 Topics: Aged; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Placebos; Quality of Life; Treatment Outcome	2009
A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:3 Topics: Adolescent; Adult; Bipolar Disorder; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Galantamine; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Nootropic Agents; Pilot Projects; Reaction Time; Young Adult	2009
Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study. Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:2 Topics: Aged; Alzheimer Disease; Brain Mapping; Cholinesterase Inhibitors; Cognition Disorders; Face; Follow-Up Studies; Galantamine; Humans; Magnetic Resonance Imaging; Neuropsychological Tests; Recognition, Psychology; Visual Perception	2009
The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. International journal of geriatric psychiatry, 2010, Volume: 25, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Double-Blind Method; Female; Galantamine; Humans; Male; Neuropsychological Tests; Nootropic Agents; Severity of Illness Index	2010
Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. CNS neuroscience & therapeutics, 2009,Winter, Volume: 15, Issue:4 Topics: Adolescent; Adult; Aged; Aspartic Acid; Bipolar Disorder; Brain Mapping; Choline; Cholinesterase Inhibitors; Cognition Disorders; Female; Galantamine; Humans; Magnetic Resonance Spectroscopy; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Protons; Young Adult	2009
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophrenia research, 2011, Volume: 125, Issue:2-3 Topics: Adult; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Galantamine; Humans; Injections, Intramuscular; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Psychiatric Status Rating Scales; Psychometrics; Risperidone; Schizophrenia	2011
Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. Journal of Alzheimer's disease : JAD, 2011, Volume: 27, Issue:3 Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Cognition; Cognition Disorders; Female; Follow-Up Studies; Galantamine; Humans; Internationality; Male; Retrospective Studies; Time Factors; Treatment Outcome	2011
[New approach to gait disorders therapy in late stages of Parkinson's disease]. Advances in gerontology = Uspekhi gerontologii, 2012, Volume: 25, Issue:2 Topics: Aged; Biological Availability; Cholinesterase Inhibitors; Cognition Disorders; Combined Modality Therapy; Female; Gait; Gait Disorders, Neurologic; Galantamine; Humans; Male; Middle Aged; Monitoring, Physiologic; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Synaptic Transmission; Transcranial Magnetic Stimulation; Treatment Outcome	2012
Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine. Sleep, 2003, Aug-01, Volume: 26, Issue:5 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Drug Administration Schedule; Female; Galantamine; Humans; Male; Prevalence; Severity of Illness Index; Sleep Wake Disorders	2003
Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. International journal of geriatric psychiatry, 2003, Volume: 18, Issue:10 Topics: Aged; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Female; Galantamine; Hallucinations; Humans; Male; Mental Status Schedule; Nootropic Agents; Parkinson Disease; Treatment Outcome	2003
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. Archives of gerontology and geriatrics. Supplement, 2004, Issue:9 Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Galantamine; Humans; Indans; Male; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index	2004
Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. NeuroImage, 2004, Volume: 23, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Cholinergic Fibers; Cognition Disorders; Dominance, Cerebral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Galantamine; Gyrus Cinguli; Hippocampus; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Long-Term Care; Magnetic Resonance Imaging; Male; Mental Recall; Middle Aged; Neuropsychological Tests; Pattern Recognition, Visual	2004
Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients. Progress in neuro-psychopharmacology & biological psychiatry, 2005, Volume: 29, Issue:1 Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Injuries; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Galantamine; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Psychomotor Performance; Rivastigmine; Treatment Outcome	2005
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. European journal of clinical pharmacology, 2005, Volume: 61, Issue:5-6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Italy; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Time Factors; Treatment Outcome	2005
Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? Journal of neurology, neurosurgery, and psychiatry, 2005, Volume: 76, Issue:10 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Female; Follow-Up Studies; Galantamine; Humans; Lactones; Male; Memory Disorders; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Piracetam; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Severity of Illness Index; Sulfones	2005
Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Neurobiology of aging, 2006, Volume: 27, Issue:1 Topics: Acetylcholine; Aged; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Drug Delivery Systems; Female; Galantamine; Hippocampus; Humans; Memory; Neural Inhibition; Recovery of Function; Severity of Illness Index; Synaptic Transmission; Treatment Outcome	2006
Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2006, Apr-11, Volume: 174, Issue:8 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Female; Galantamine; Humans; Male; Placebos; Severity of Illness Index; Treatment Outcome	2006
Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. International journal of geriatric psychiatry, 2007, Volume: 22, Issue:4 Topics: Activities of Daily Living; Aged; Cholinesterase Inhibitors; Cognition Disorders; Combined Modality Therapy; Computer-Assisted Instruction; Donepezil; Female; Galantamine; Humans; Indans; Intelligence; Longitudinal Studies; Male; Memory Disorders; Middle Aged; Neuropsychological Tests; Nootropic Agents; Orientation; Phenylcarbamates; Piperidines; Problem Solving; Retrospective Studies; Rivastigmine; Software; Treatment Outcome	2007
A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. International clinical psychopharmacology, 2007, Volume: 22, Issue:2 Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; Cognition; Cognition Disorders; Color Perception; Double-Blind Method; Drug Therapy, Combination; Female; Galantamine; Humans; Male; Mental Recall; Mental Status Schedule; Middle Aged; Nootropic Agents; Recognition, Psychology; Schizophrenia; Treatment Outcome	2007
Galantamine treatment of vascular dementia: a randomized trial. Neurology, 2007, Jul-31, Volume: 69, Issue:5 Topics: Acetylcholine; Activities of Daily Living; Adult; Aged; Behavioral Symptoms; Brain; Brain Chemistry; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Dementia, Vascular; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Neuropsychological Tests; Placebos; Recovery of Function; Treatment Outcome	2007
Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology, 2007, Oct-09, Volume: 69, Issue:15 Topics: Age Factors; Aged; Alzheimer Disease; Apolipoprotein E4; Atrophy; Biomarkers; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Galantamine; Genetic Predisposition to Disease; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Fibers, Myelinated; Neuropsychological Tests; Predictive Value of Tests; Prognosis	2007
Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. Journal of neural transmission. Supplementum, 2007, Issue:72 Topics: Aged; Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Long-Term Care; Male; Mental Status Schedule; Middle Aged; Oxidative Stress; Piperidines; Thioctic Acid	2007
Galantamine for the treatment of cognitive impairments in people with schizophrenia. The American journal of psychiatry, 2008, Volume: 165, Issue:1 Topics: alpha7 Nicotinic Acetylcholine Receptor; Attention; Brief Psychiatric Rating Scale; Cholinesterase Inhibitors; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Galantamine; Humans; Male; Middle Aged; Neuropsychological Tests; Practice, Psychological; Receptors, Nicotinic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Wechsler Scales	2008
Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology, 2008, May-27, Volume: 70, Issue:22 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Cohort Studies; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Retrospective Studies	2008
High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophrenia research, 2008, Volume: 102, Issue:1-3 Topics: Ambulatory Care; Antipsychotic Agents; Attention; Cholinesterase Inhibitors; Cognition Disorders; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Galantamine; Humans; Inhibition, Psychological; Male; Memory; Middle Aged; Neuropsychological Tests; Placebos; Regression Analysis; Schizophrenia; Schizophrenic Psychology; Smoking; Treatment Outcome	2008
Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. International journal of geriatric psychiatry, 2001, Volume: 16, Issue:9 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Galantamine; Humans; Male; Mental Status Schedule; Treatment Outcome	2001
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. Journal of neurology, neurosurgery, and psychiatry, 2001, Volume: 71, Issue:5 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Galantamine; Humans; Male; Neuropsychological Tests; Receptors, Nicotinic; Severity of Illness Index; Synaptic Transmission; Time Factors; Treatment Outcome	2001

Other Studies

44 other study(ies) available for galantamine and Cognition Disorders

Article	Year
Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2017, Volume: 13, Issue:10 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Double-Blind Method; Female; Galantamine; Goals; Humans; Indans; Male; Multicenter Studies as Topic; Outcome Assessment, Health Care; Piperidines; Severity of Illness Index	2017
Significance of the nicotinic alpha7 receptor in cognition and antipsychotic-like behavior in the rat. Behavioural brain research, 2017, 08-30, Volume: 333 Topics: Acrylamides; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Avoidance Learning; Cognition Disorders; Discrimination, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Furans; Galantamine; Male; Phencyclidine; Rats; Rats, Wistar; Statistics, Nonparametric; Time Factors	2017
Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice. Journal of neuroinflammation, 2018, Apr-18, Volume: 15, Issue:1 Topics: Animals; Cell Line, Transformed; Cognition Disorders; Cytokines; Galantamine; Hippocampus; Inflammation; Lipopolysaccharides; Male; Maze Learning; Memory; Mice, Inbred Strains; Microglia; Nerve Tissue Proteins; Neuronal Plasticity; Nootropic Agents; RNA, Messenger; Silver Staining	2018
Galantamine reversed early postoperative cognitive deficit via alleviating inflammation and enhancing synaptic transmission in mouse hippocampus. European journal of pharmacology, 2019, Mar-05, Volume: 846 Topics: Animals; CA1 Region, Hippocampal; Cognition Disorders; Cytokines; Excitatory Postsynaptic Potentials; Galantamine; Inflammation; Interleukin-10; Interleukin-1beta; Interleukin-4; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Microglia; Neurons; Postoperative Complications; Receptors, AMPA; Synaptic Transmission; Tibial Fractures; Tumor Necrosis Factor-alpha	2019
[Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina]. Medicina, 2013, Volume: 73, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Argentina; Child; Child, Preschool; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Dementia, Vascular; Donepezil; Drug Prescriptions; Female; Galantamine; Humans; Indans; Infant; Male; Memantine; Middle Aged; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Young Adult	2013
Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, Sep-11, Volume: 33, Issue:37 Topics: Acetylcholine; Animals; Aspartic Acid; Choice Behavior; Choline; Cholinesterase Inhibitors; Cognition Disorders; Executive Function; Galantamine; Inositol; Lactic Acid; Locomotion; Mice; Mice, Inbred C57BL; Mice, Transgenic; Photic Stimulation; Prefrontal Cortex; Psychomotor Performance; RNA Splicing; Taurine; Vesicular Acetylcholine Transport Proteins	2013
The protective effects of Cyperus rotundus on behavior and cognitive function in a rat model of hypoxia injury. Pharmaceutical biology, 2014, Volume: 52, Issue:12 Topics: Animals; Behavior, Animal; Cognition Disorders; Cyperus; Disease Models, Animal; Dose-Response Relationship, Drug; Galantamine; Hypoxia; Male; Medicine, Ayurvedic; Motor Activity; Plant Extracts; Pyrithioxin; Rats; Rats, Wistar; Sodium Nitrite	2014
Galanthamine, an acetylcholine inhibitor, prevents prepulse inhibition deficits induced by adolescent social isolation or MK-801 treatment. Brain research, 2014, Nov-17, Volume: 1589 Topics: Age Factors; Animals; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Dizocilpine Maleate; Galantamine; Male; Prepulse Inhibition; Rats; Rats, Wistar; Social Isolation; Spatial Learning	2014
Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice. Neuroscience, 2015, Jul-09, Volume: 298 Topics: Aconitine; alpha7 Nicotinic Acetylcholine Receptor; Amyloid beta-Peptides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Galantamine; Gene Expression Regulation; Male; Maze Learning; Mice; Mice, Inbred BALB C; Nicotinic Agonists; Nicotinic Antagonists; Peptide Fragments; Psychomotor Performance; Quinuclidines; RNA, Messenger; Time Factors	2015
Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. British journal of pharmacology, 2008, Volume: 155, Issue:3 Topics: Animals; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Dizocilpine Maleate; Drug Administration Schedule; Drug Therapy, Combination; Galantamine; Male; Maze Learning; Motor Activity; Rats; Rats, Wistar; Receptors, Serotonin; Scopolamine; Serotonin Antagonists; Sulfonamides; Thiophenes; Yawning	2008
Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dementia and geriatric cognitive disorders, 2009, Volume: 27, Issue:5 Topics: Aged; Cognition Disorders; Cohort Studies; Cross-Sectional Studies; Databases, Factual; Dementia; Diagnosis, Differential; Female; Galantamine; Germany; Humans; Magnetic Resonance Imaging; Male; Memantine; Middle Aged; Multicenter Studies as Topic; Nootropic Agents; Phenotype; Quality Control; Tomography, X-Ray Computed	2009
Acetylcholinesterase inhibitors enhance cognitive functions in rats following hypobaric hypoxia. Behavioural brain research, 2009, Oct-12, Volume: 203, Issue:1 Topics: Acetylcholine; Acetylcholinesterase; Air Pressure; Animals; Cerebral Cortex; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Galantamine; Hippocampus; Hypoxia; Male; Maze Learning; Memory; Neurons; Neuroprotective Agents; Physostigmine; Random Allocation; Rats; Rats, Sprague-Dawley	2009
Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease. Brain research, 2009, Jul-14, Volume: 1280 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Ventricles; Cognition Disorders; Disease Models, Animal; Galantamine; Hippocampus; Injections, Intraventricular; Long-Term Potentiation; Male; Memory; Memory Disorders; Mice; Mice, Inbred C57BL; Neurotoxins; Nootropic Agents; Peptide Fragments	2009
Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. Journal of molecular neuroscience : MN, 2010, Volume: 40, Issue:1-2 Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Brain Chemistry; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ferrets; Galantamine; Gastrointestinal Diseases; Humans; Mice; Scopolamine; Synaptic Transmission; Treatment Outcome	2010
Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat. Brain research bulletin, 2011, May-30, Volume: 85, Issue:3-4 Topics: Acetylcholinesterase; Analysis of Variance; Animals; Brain; Caffeic Acids; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Galantamine; Glutathione; Hippocampus; Kainic Acid; Lactones; Lipid Peroxidation; Maze Learning; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Nootropic Agents; Rats; Rats, Wistar; Succinate Dehydrogenase; Sulfones; Superoxide Dismutase; Tumor Necrosis Factor-alpha	2011
Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: clinical significance. Neurotoxicology, 2011, Volume: 32, Issue:6 Topics: Animals; Behavior, Animal; Brain; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models, Animal; Extinction, Psychological; Female; Galantamine; Guinea Pigs; Lethal Dose 50; Maze Learning; Motor Activity; Neuroprotective Agents; Nootropic Agents; Reaction Time; Soman; Time Factors	2011
Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology, 2012, Volume: 220, Issue:3 Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Cognition; Cognition Disorders; Disease Models, Animal; Galantamine; Glutamic Acid; Kynurenic Acid; Kynurenine; Male; Nootropic Agents; Prefrontal Cortex; Rats; Rats, Wistar; Receptors, Nicotinic; Schizophrenia	2012
8-[2-(2-Pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid and its diastereomers improve age-related cognitive deterioration. Lipids, 2012, Volume: 47, Issue:7 Topics: Aging; Animals; Caprylates; Cholinesterase Inhibitors; Cognition Disorders; Galantamine; Male; Memory Disorders; Mice	2012
Psychopharmacologic intervention after hemorrhagic basal ganglia damage. Journal of the neurological sciences, 2012, Nov-15, Volume: 322, Issue:1-2 Topics: Adult; Basal Ganglia Hemorrhage; Cognition Disorders; Galantamine; Glasgow Coma Scale; Humans; Male; Mental Disorders; Methylphenidate; Neuropsychological Tests; Nootropic Agents; Tomography Scanners, X-Ray Computed	2012
Cognitive decline and treatment options for patients with vascular dementia. Acta neurologica Scandinavica. Supplementum, 2002, Volume: 178 Topics: Aged; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Diagnosis, Differential; Galantamine; Humans; Neuropsychological Tests; Nootropic Agents; Treatment Outcome	2002
Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Stroke, 2003, Volume: 34, Issue:2 Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Diagnosis, Differential; Donepezil; Galantamine; Humans; Indans; Neuropsychological Tests; Nootropic Agents; Piperidines; Severity of Illness Index; Terminology as Topic; Treatment Outcome	2003
The impact of drugs against dementia on cognition in aging and mild cognitive impairment. Pharmacopsychiatry, 2003, Volume: 36 Suppl 1 Topics: Adult; Aged; Aged, 80 and over; Aging; Cognition; Cognition Disorders; Dementia; Donepezil; Female; Galantamine; Ginkgo biloba; Humans; Indans; Male; MEDLINE; Middle Aged; Nootropic Agents; Piperidines; Plant Extracts	2003
Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke, 2004, Volume: 35, Issue:4 Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Controlled Clinical Trials as Topic; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine; Stroke; Terminology as Topic	2004
A case study in the treatment of dementia with Lewy bodies. Acta psychiatrica Scandinavica, 2004, Volume: 110, Issue:1 Topics: Aged; Aged, 80 and over; Carbamates; Cognition Disorders; Donepezil; Drug Resistance; Female; Galantamine; Hallucinations; Humans; Indans; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Psychomotor Agitation; Rivastigmine; Social Behavior	2004
Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:10 Topics: Aged; Alzheimer Disease; Botulinum Toxins, Type A; Cholinesterase Inhibitors; Cognition Disorders; Dystonia; Female; Galantamine; Humans; Neuromuscular Agents; Neuropsychological Tests; Severity of Illness Index; Syndrome	2004
Regulatory authorities review use of galantamine in mild cognitive impairment. BMJ (Clinical research ed.), 2005, Feb-05, Volume: 330, Issue:7486 Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Drug Approval; Galantamine; Humans; United Kingdom	2005
Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury. Journal of clinical psychopharmacology, 2005, Volume: 25, Issue:5 Topics: Adult; Antipsychotic Agents; Brain Hemorrhage, Traumatic; Cholinesterase Inhibitors; Cognition Disorders; Female; Galantamine; Humans; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenic Psychology	2005
Galantamine in the treatment of vascular dementia. International psychogeriatrics, 2003, Volume: 15 Suppl 1 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Galantamine; Humans	2003
Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study. Brain : a journal of neurology, 2006, Volume: 129, Issue:Pt 1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Case-Control Studies; Chi-Square Distribution; Cholinesterase Inhibitors; Cognition Disorders; Female; Galantamine; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests	2006
Galantamine treatment of cognitive impairment in bipolar disorder: four cases. Bipolar disorders, 2006, Volume: 8, Issue:2 Topics: Adult; Bipolar Disorder; Cholinesterase Inhibitors; Cognition Disorders; Female; Galantamine; Humans; Male; Middle Aged	2006
Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement? Schizophrenia research, 2006, Volume: 85, Issue:1-3 Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Chronic Disease; Cognition Disorders; Drug Therapy, Combination; Galantamine; Humans; Neuropsychological Tests; Pilot Projects; Schizophrenia; Severity of Illness Index	2006
Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006, Volume: 14, Issue:7 Topics: Aged; Alkaloids; Alzheimer Disease; Brain; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Diagnostic and Statistical Manual of Mental Disorders; Galantamine; Geriatric Psychiatry; Health Services for the Aged; Humans; Phenylcarbamates; Professional-Family Relations; Rivastigmine; Sesquiterpenes; Tacrine; United States	2006
Adjuvant galantamine for cognitive dysfunction in a patient with bipolar disorder. Journal of psychiatric practice, 2006, Volume: 12, Issue:5 Topics: Alzheimer Disease; Antimanic Agents; Bipolar Disorder; Cholinesterase Inhibitors; Cognition Disorders; Diagnosis, Differential; Female; Galantamine; Humans; Middle Aged; Neuropsychological Tests; Severity of Illness Index	2006
The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2007, Volume: 32, Issue:6 Topics: Amyloid beta-Peptides; Animals; Cognition Disorders; Conditioning, Psychological; Cues; Dopamine; Extracellular Space; Fear; Galantamine; Hippocampus; Injections, Intraventricular; Male; Memory; Mice; Mice, Inbred ICR; Muscarinic Antagonists; Peptide Fragments; Receptors, Nicotinic; Recognition, Psychology; Scopolamine; Synaptic Transmission	2007
Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials. Drugs & aging, 2007, Volume: 24, Issue:1 Topics: Aged; Alzheimer Disease; Cognition Disorders; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Galantamine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nootropic Agents	2007
Posttraumatic stress disorder-like symptoms after treatment with acetylcholinesterase inhibitors. The Journal of neuropsychiatry and clinical neurosciences, 2007,Winter, Volume: 19, Issue:1 Topics: Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Magnetic Resonance Imaging; Male; Middle Aged; Piperidines; Stress Disorders, Post-Traumatic; Stroke; Veterans	2007
Post-ischemic continuous administration of galantamine attenuates cognitive deficits and hippocampal neurons loss after transient global ischemia in gerbils. Neuroscience letters, 2007, Apr-06, Volume: 416, Issue:1 Topics: Animals; Avoidance Learning; Behavior, Animal; Brain Ischemia; Cognition Disorders; Disease Models, Animal; Galantamine; Gerbillinae; Hippocampus; Memory; Mice; Motor Activity; Neurons; Nootropic Agents	2007
Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl). Archives of gerontology and geriatrics, 2007, Volume: 44 Suppl 1 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Disability Evaluation; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Male; Mental Disorders; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index	2007
Galantamine for Alzheimer's disease and mild cognitive impairment. Neuroepidemiology, 2007, Volume: 28, Issue:2 Topics: Alzheimer Disease; Cognition Disorders; Delayed-Action Preparations; Galantamine; Humans; Nootropic Agents; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome	2007
The impact of galantamine on cognition and mood during electroconvulsive therapy: a pilot study. Journal of psychiatric research, 2008, Volume: 42, Issue:7 Topics: Cholinesterase Inhibitors; Cognition Disorders; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Galantamine; Heart Arrest; Humans; Male; Middle Aged; Neuromuscular Depolarizing Agents; Neuropsychological Tests; Pilot Projects; Severity of Illness Index; Succinylcholine	2008
A rabbit model of Alzheimer's disease: valid at neuropathological, cognitive, and therapeutic levels. Journal of Alzheimer's disease : JAD, 2007, Volume: 11, Issue:3 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blinking; Cerebellum; Cholinesterase Inhibitors; Cognition Disorders; Conditioning, Classical; Disease Models, Animal; Galantamine; Hippocampus; Male; Neurons; Neuropsychological Tests; Rabbits; tau Proteins	2007
[Alzheimer drugs for mild cognitive impairment]. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater, 2007, Volume: 21, Issue:3 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Early Diagnosis; Galantamine; Humans; Memantine; Neuropsychological Tests; Nootropic Agents; Treatment Failure	2007
For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not? International psychogeriatrics, 2008, Volume: 20, Issue:2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Neuropsychological Tests; Piperidines; Severity of Illness Index; Treatment Outcome	2008
Treatment for MCI: is the evidence sufficient? Neurology, 2008, May-27, Volume: 70, Issue:22 Topics: Alzheimer Disease; Clinical Trials as Topic; Cognition Disorders; Galantamine; Humans	2008